CEO, HELIO GENOMICS
WHY: Developing AI-enabled blood tests to identify early stages of blood, breast and liver cancers from a blood draw; one of Orange County’s better-funded medical startups.
IN THE NEWS: Plans to ramp up its Irvine operations following the December launch of its inaugural product. HelioLiver is a laboratory developed test that detects early-stage liver cancers at a higher rate than traditional detection methods; launched via a commercial partnership with Fulgent Genetics Inc. (Nasdaq: FLGT). NOTABLE: 2022 Business Journal Innovator of the Year Award winner.
QUOTABLE: “We’re on the precipice of something great—we can really revolutionize liver cancer, a problem around the globe.”
